Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-10-01 / Anticancer Res 2020 Oct;40(10):5765-5776NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-09-28 / J Cell Biochem 2021 Jan;122(1):3-15The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model
/in International Publications, Newcastle Disease Virus /von 2020-09-28 / J Med Virol 2021 06;93(6):3890-3898Anti-Cancer Activity of Curcumin on Multiple Myeloma
/in Curcuma, International Publications /von 2020-09-18 / 2020 Sep;Obstacles against the Marketing of Curcumin as a Drug
/in Curcuma, International Publications /von 2020-09-10 / Int J Mol Sci 2020 Sep;21(18)Exhaustion of Protective Heat Shock Response Induces Significant Tumor Damage by Apoptosis after Modulated Electro-Hyperthermia Treatment of Triple Negative Breast Cancer Isografts in Mice
/in Breast Cancer, Hyperthermia, International Publications /von 2020-09-10 / Cancers (Basel) 2020 Sep;12(9)Quo Vadis Oncological Hyperthermia (2020)?
/in Hyperthermia, International Publications /von 2020-09-04 / Front Oncol 2020;10:1690Pilot study on outcome and antitumor efficacy of an autologous cancer cell vaccine applied in patients with advanced solid tumors.
/in Dendritic Cells, International Publications /von 2020-08-31 / J Clin Oncol 38: 2020 (suppl; abstr 3000)Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models
/in Hyperthermia, International Publications /von 2020-08-29 / Int J Mol Sci 2020 Aug;21(17)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de